For research use only. Not for therapeutic Use.
Enzalutamide (CAS 915087-33-1), also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer.
| Catalog Number | A001158 |
| CAS Number | 915087-33-1 |
| Synonyms | Enzalutamide; |
| Molecular Formula | C21H16F4N4O2S |
| Purity | ≥95% |
| Target | Androgen Receptor |
| Solubility | >23.2mg/mL in DMSO |
| Storage | 3 years -20C powder |
| Overview of Clinical Research | Enzalutamide is an androgen receptor antagonist. The phase III study on prostate cancer starts in 2020. |
| IUPAC Name | 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide |
| InChI | InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30) |
| InChIKey | WXCXUHSOUPDCQV-UHFFFAOYSA-N |
| SMILES | CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C |
| Reference | <br /> |
